Recentin (cediranib) / AstraZeneca - LARVOL DELTA

NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer (ESMO 2025) - P2 | "Methods Eligible patients (pts) had at least 1 prior line of chemotherapy (no more than 2) with prior endocrine and immunotherapy (prior lenvatinib/pembrolizumab excluded) allowed, ECOG 0-1. Conclusions The combinations of O+D, O+CA and C+D did not meet prespecified endpoints for significance in an unselected population. Further evaluation of molecular subgroups and prior immunotherapy treatment is necessary to determine if there are any signals warranting future investigation."

Clinical • Metastases • P2 data • Endometrial Cancer • Oncology • Solid Tumor

Efficacy and safety of PARP inhibitors monotherapy or combination therapy with anti-angiogenics in ovarian cancer: a network meta-analysis. (PubMed, Front Oncol) - "Besides, niraparib+bevacizumab ranked first in improving PFS, followed by olaparib+ cediranib...In monotherapy, senaparib has shown good efficacy...A reasonable treatment plan should be selected based on the individual conditions of patients. https://www.crd.york.ac.uk/prospero/, identifier CRD 420251003413."

Journal • Monotherapy • Retrospective data • Review • Cervical Cancer • Oncology • Ovarian Cancer • Solid Tumor • Uterine Cancer

DAPPER: Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov) - P2 | N=90 | Active, not recruiting | Sponsor: University Health Network, Toronto | Trial completion date: Jan 2026 ➔ Jan 2027 | Trial primary completion date: Jan 2026 ➔ Jan 2027

IO biomarker • Pan tumor • Trial completion date • Trial primary completion date • Colorectal Cancer • Leiomyosarcoma • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Sarcoma • Solid Tumor • HRD

Comparing durvalumab, olaparib, and cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian cancer with prior bevacizumab: the phase II NRG-GY023 trial. (PubMed, Clin Cancer Res) - "In PROC patients with prior bevacizumab, all experimental arms failed to reach the primary objective of improving PFS compared with SOC."

Journal • Monotherapy • P2 data • Platinum resistant • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy (ESMO 2024) - P3 | "Stratification was by country, tumour BRCA (tBRCA), prior bevacizumab, platinum-free interval, surgery at relapse. Maintenance O+C did not improve efficacy compared to O. PARPi alone led to better than anticipated outcomes. Translational work to identify patients who might benefit most from this approach is ongoing."

Clinical • Late-breaking abstract • P3 data • Gynecologic Cancers • Oncology • Ovarian Cancer • BRCA

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005. (PubMed, J Clin Oncol) - "The cediranib-containing arms demonstrated clinical activity on the basis of PFS but were not superior compared with SOC."

Journal • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. (PubMed, J Clin Oncol) - "Cediranib combined with olaparib improved rPFS compared with olaparib alone in men with mCRPC. This combination was associated with an increased incidence of grades 3-4 adverse events. BRCA2-mutated subgroups treated with olaparib with or without cediranib were associated with a numerically longer median rPFS."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA2 • HRD

Randomized Phase 2 Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma. (PubMed, Clin Cancer Res) - "The study did not meet its endpoints for ORR. Although both TKIs provided clinical benefit, the outcomes may have been attenuated in patients who had progressed ≤6 months before enrollment, potentially accounting for the low response rates."

Journal • P2 data • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial. (PubMed, Clin Cancer Res) - "A second course of olaparib can be safely administered to women with gBRCAm-HGSOC but is only modestly efficacious."

Journal • P2 data • Acute Myelogenous Leukemia • Fatigue • Hematological Disorders • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor • BRCA1 • BRCA2 • HRD

WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer (KCRS 2024) - P2 | "Cediranib + Olaparib (a PARP inhibitor), 3...Volrustomig (anti PD-1/CTLA4 bispecific) and 5. Rilvegostomig (anti PD-1/TIGIT bispecific)...WIRE may identify novel biomarkers of response and toxicity, to inform treatment selection for patients. The data generated will be a foundation for further trials of these IMPs in advanced disease."

Clinical • IO biomarker • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • TIGIT

Efficacy of novel agents in the treatment of acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis (ASH 2025) - "Newer agents included for AML were Guadectiabine, Magrolimab, Alvocidib, Enasidenib, Flotetuzumab, Vadastuximab, Mitoxantrone, Pevonedistat, Entospletinib, Eprenetapopt, Belinostat, Onvansertib, Panobinostat, Cediranib Maleate, Nilotinib, Emavusertib, and anti-CD45 antibody (DOTA-BC8). The newer agents investigated for MDS included Rigosertib, Imetelstat, Pembrolizumab, Enasidenib, Sabatolimab, Ivosidenib, Elitercept, Pevonedistat, Emavusertib, Atezolizumab, and Olutasidenib...All patients were treated concomitantly with either azacitidine (77%) or decitabine (23%)... This meta-analysis and systematic review demonstrate promising efficacy for novel agents in AML and MDS patients. There is a need for prospective trials with larger patient populations to investigate these agents further."

Retrospective data • Review • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neutropenia • TP53

Lost in translation: Do preclinical studies predict clinical failure in GBM? (SNO 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (SNO 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (WFNOS 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Oncology • Solid Tumor

Lost in translation: Do preclinical studies predict clinical failure in GBM? (WFNOS 2025) - "For the trials evaluated, no preclinical brain:plasma (B/P) data were reported for enzastaurin, cilengitide, nimotuzumab, Depatux-M, or bevacizumab, although IgG typically has a B/P ≈1%...The best response for each drug compared to relevant control (relative increase in median survival) was 22% (nimotuzumab), 31% (marizomib), 36% (sunitinib CD) / 5% (sunitinib PD), 63% (bevacizumab/temozolomide), 140% (imatinib), 157% (Depatux-M), 220% (veliparib/temozolomide), 300% (cediranib); median survival was not reached for cilengitide...The stunning lack of clinical progress in GBM is deeply discouraging, but is consistent with underwhelming preclinical testing and the contextual interpretation of those results. Acknowledging multifaceted reasons for failed clinical trials, a more rigorous and critical approach should be used in preclinical studies, coupled with follow-up surgical window of opportunity studies, to identify and promote only the most promising therapies into..."

Preclinical • Brain Cancer • CNS Disorders • Glioblastoma • Glioma • Oncology • Solid Tumor

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. (PubMed, NAR Cancer) - "To overcome this resistance, we found that treatment with the receptor tyrosine kinase inhibitor, cediranib, previously reported to suppress expression of downstream HDR factors, resensitizes 53BP1 and REV7-knockout cells to PARPi treatment. Our findings identify key pathways driving PARPi resistance in IDH1-mutant cancers and highlight potential therapeutic strategies to overcome this resistance."

Journal • Oncology • Transplantation • IDH1 • IDH2 • TP53BP1

Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI. (PubMed, Abdom Radiol (NY)) - P2 | "The largest decrease in LAC/PYR ratio was in the patient treated with cediranib monotherapy (-21%), followed by a smaller reduction in a patient receiving the combination of cediranib and olaparib (-14%). KEY TAKE HOME MESSAGE: The study provides preliminary evidence supporting HP 13C-MRI as a promising imaging biomarker for evaluating early metabolic changes in renal cell carcinoma following neoadjuvant therapy. CLINICAL TRIALS REGISTRY: NCT03741426, Registration date: 13 November 2018."

Journal • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Identification of 2 Ubiquitin-Proteasome System-Related Subtypes in Esophageal Squamous Cell Carcinoma for Prognostic and Immunotherapeutic Response Prediction. (PubMed, J Immunother) - "Selumetinib, entinostat, and erlotinib were identified as candidate drugs for cluster 2, whereas tozasertib, alpelisib, and cediranib showed higher suitability for cluster 1. Ten potential biomarkers, 13 transcription factors, and 2 miRNAs were characterized. This study elucidates the role of UPS in ESCC progression and provides a framework for personalized treatment strategies."

IO biomarker • Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma • Targeted Protein Degradation • CD8 • TP53

Ex Vivo Drug Sensitivity Evaluation of a ZMYM2: : FGFR1 Fusion-Positive 8p11 Myeloproliferative Syndrome (EMS) Leukemia (ASH 2023) - "Bortezomib and Axitinib exhibited high efficacy on the patient's sample...Other FGFR inhibitors, including Olverematinib, AZD4547, Axitinib, Cediranib, Dovitinib, and Lenvatinib, also demonstrated exquisite sensitivity. Despite extensive screening, no other single agents or drug combinations exhibited increased effectiveness in the ZMYM2: : FGFR1 transformed BaF3 cells except for Trametinib, a MEK inhibitor, and the combination of Belvarafenib (RAF inhibitor) and Gilteritinib (FLT3 inhibitor)... Ex vivo drug sensitivity assays demonstrated the highly selective efficacy of FGFR inhibitors in ZMYM2: : FGFR1 fusion-positive leukemia cells and a fusion-expressing BaF3 cell line. Mutations in the FGFR1 kinase domain (ZMYM2: : FGFR1 F1171L) could contribute to Ponatinib insensitivity. These ex vivo drug screening results provide further support for ongoing clinical trials which are investigating the use of single agent Pemigatinib and other FGFR1 inhibitors for the..."

Preclinical • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation • FGFR1 • FLT3 • RUNX1 • ZMYM2

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer. (PubMed, Res Sq) - "Conversely, cytoskeletal redistribution was seen in transcriptomic data from patient tumors without clinical benefit. These findings emphasize the importance of combining immune, metabolic and cytoskeletal profiling-based treatment strategies for the future clinical studies in recurrent EOC."

Journal • P2 data • Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor

Plasma Tie2 is a valid biomarker for VEGF inhibitors (VEGFi) in endometrial cancer: Evidence from the COPELIA three-arm randomised controlled trial (RCT) (ESMO 2025) - P2 | "In ovarian, colorectal and biliary tract cancer, using bevacizumab or cediranib, we showed that a reduction in plasma Tie2 within 9 weeks of starting a VEGFi was associated with a PFS hazard ratio (HR) between 0.55-0.7 in favour of VEGFi...Methods COPELIA was a RCT in platinum-pretreated advanced/recurrent EC of weekly paclitaxel ( P ) +/- cediranib ( PC ) or cediranib with olaparib ( CO )...Conclusions Tie2-defined vascular response identified patients with EC who significantly benefited from PC or CO . Vascular non-responders did not benefit from C ( PC / CO ) and experienced significantly more high-grade adverse events than those treated with P ."

Biomarker • Clinical • Biliary Cancer • Biliary Tract Cancer • Colorectal Cancer • Endometrial Cancer • Oncology • Solid Tumor

Telling it as it is: Quality of life outcomes associated with maintenance olaparib and cediranib following a response to chemotherapy in relapsed platinum-sensitive ovarian cancer (ESMO 2025) - P3 | "Table: 1089P Domain Mean (SD) score at baseline Mean (SD) score at cycle 4 Mean (SD) change from baseline at cycle 4 O (n=131) O+C (n=129) O (n=131) O+C (n=129) O (n=131) O+C (n=129) QLU-C10D health utility 0.80 (0.179) 0.80 (0.196) 0.74 (0.192) 0.70 (0.204) -0.06 (0.125) -0.10 (0.131) -0.04 (95% CI: -0.08 to -0.01) p=0.01 Diarrhoea symptom item 5.8 (13.79) 4.8 (12.88) 9.6 (19.24) 22.7 (23.64) 4.3 (19.07) 18.0 (23.05) 13.7 (95% CI: 8.4 to 19.0) p<0.001 Fatigue symptom scale 25.3 (22.21) 23.8 (21.88) 31.2 (23.61) 36.3 (24.71) 5.4 (19.32) 14.0 (18.50) 8.6 (95% CI: 3.9 to 13.3) p<0.001 Nausea/Vomiting symptom scale 4.0 (10.48) 4.5 (13.38) 15.6 (18.76) 17.1 (18.45) 11.3 (18.41) 12.5 (17.54) 1.2 (95% CI: -3.2 to 5.7) p=0.58 Conclusions QoL was impacted with maintenance therapy for platinum-sensitive relapsed ovarian cancer, more so with O+C than O . Health utility and common symptoms were worse, particularly diarrhoea, persisting beyond 12 weeks and returning..."

Clinical • HEOR • Platinum sensitive • Oncology • Ovarian Cancer • Solid Tumor

Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation. (PubMed, Bioorg Chem) - "Further, a charge-convertible polymer-based nanoformulation (18-PEG-PLL/DMMA nanoparticles) for targeted drug delivery of 18 was developed. Encouragingly, the nanoformulation demonstrated a cytotoxicity-devoid profile towards normal cells owing to its pH-sensitive behavior and manifested selective cell growth inhibition against solid tumor cells, possibly due to the EPR effect."

Journal • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Solid Tumor • FLT4 • PARP2

NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P3 | N=579 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2026

Platinum sensitive • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2